0000000000081608
AUTHOR
V. Panzarella
showing 25 related works from this author
Is resective surgery still the best practice for ONJ stage III? A case report of a conservative therapy
2017
DOCTORAL: THE FREE APP FOR TUTORING IN SUPPORTIVE ORAL CARE
2018
To introduce the version 2.0 of DoctOral free app, created for tutoring medical/dental professionals (and students) in the clinical recognition of oral lesions and dental treatment planning in patients at risk of ONJ drug- related.
GOTeC: INTERDISCIPLINARY TUMOR BOARD FOR THE DIAGNOSIS AND TREATMENTS OF HEAD AND NECK CANCERS
2018
Expression of apoptosis and proliferation regulating markers in OSCC
2007
L’odontoiatria a misura del paziente con patologia osteometabolica a rischio di osteonecrosi delle ossa mascellari da farmaci.
2016
L’osteonecrosi delle ossa mascellari (ONJ) da farmaci è una severa patologia odontoiatrica, recentemente defi nita come «una reazione avversa farmacocorrelata, caratterizzata dalla progressiva distruzione e necrosi dell’osso mandibolare e/o mascellare di soggetti esposti al trattamento con farmaci per cui sia accertato un aumentato rischio di malattia, in assenza di un pregresso trattamento radiante»1-3. I pazienti osteometabolici a rischio di sviluppare l’ONJ sono quelli sottoposti a terapia con bisfosfonati (in particolare aminobisfosfonati o Nitrogen-containing BisPhosphonate/NBP) e, più recentemente, con denosumab (anticorpo monoclonale anti-RANKL)4. Tali farmaci antiriassorbitivi carat…
Oral Lichen Planus: a new experimental therapeutic protocol by means of oxygen-ozone mixture injection.
2019
Differential diagnosis of diffused oral mucosal pigmented lesion: a case of Dubreuilh’s melanosis
2019
A misleading infection in a psoriatic patient: a challenging diagnosis of orocutaneous leishmaniasis
2019
Optical Coherence Tomography (OCT) and Oral Potentially Malignant Disorders: critical review on potential diagnostic patterns
2022
Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study
2017
Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients. Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multiv…
knowledge, practice and attitude about OSCC prevention among Calabrian primary care physicians: an observational study
2018
Principal adverse events due to everolimus therapy. A systematic review of the literature
2019
Ozone insufflation and l-prf application in an idiopathic and recurrent case of osteonecrosis of the maxilla
2019
Surgical treatment of medication-related osteonecrosis of the jaws with addiction of L-PRF: preliminary results
2018
Early detection of amyloid light-chain amyloidosis: a case report of oral primary manifestation
2018
Oral health assessment in palliate patients: an exploratory preliminary survey
2017
Follow-up of non-exposed ONJ related to bisphosphonate: a two-year study
2015
Aim. Osteonecrosis of the jaw (ONJ) is a serious sideeffect of amine bisphosphonate (NBP) and/or other antiresorptive agents frequently used in the management of osteometabolic and cancer-related condition. The traditional ONJ definition exclude patients who present the non-exposed variant. However, according to recent data, staging and monitoring of ONJ should be closely linked to clinical and radiological manifestation regardless of the presence of bone exposed. The aim of this study was a descriptive analysis of a case series of patients with non-exposed ONJ (exclusively related to NBP) monitoring for two years. Methods. From 2012 to 2014, 16 patient [7 oncological (F/M=3/4; mean age=66,…
Malignant transformation of oral leukoplakia in oral squamous cell carcinoma: a case report.
2022
Development of OloHealth, a teledentistry platform for the ONJ prevention in Sicily: preliminary reports
2018
Epithelial-myoepithelial carcinoma of the minor salivary glands: a case report
2018
Concept therapy: Interdisciplinary tumor board for the diagnosis and treatments of head and neck cancer
2017
ONJ in osteometabolic patients: NO guilty verdict for teeth extraction
2018
The aim of this study is to evaluate retrospectively the impact of some variables on the risk of oNJ onset in osteometabolic non-cancer patients by logistic regression analyses.
Osteonecrosis of the jaw prevention in oncological patients: preliminary results from a teledentistry sicilian project
2019
PREVENTION OF THE DRUG-RELATED OSTEONECROSIS OF THE JAW (ONJ): PRELIMINARY DATA OF THE PROMaF PROTOCOL
2018
Stomatitis and vR-TkI: a review of current literature in 4369 patients
2018
the following review was performed to answer to the question “What is the rate of incidence of oral stomatitis in patients treated with VegF tKis?”